Eli Lilly | GJELD



Debt Endring Dato
AbbVie USD 67.14B 3.94B 2024-12
Abbott USD 13.24B 883M 2025-03
ALKERMES USD 0 0 2025-03
Amgen USD 57.38B 2.72B 2025-03
AstraZeneca USD 31.65B 1.35B 2025-03
Baxter International USD 13.13B 191M 2024-12
Biogen USD 6.3B 1.9M 2024-12
Bristol-Myers Squibb USD 49.71B 62M 2025-03
Drreddys Laboratories INR 51.08B 2.55B 2024-12
Eli Lilly USD 38.52B 4.87B 2025-03
Gilead Sciences USD 26.71B 3.46B 2024-12
GlaxoSmithKline GBP 18.43B 1.45B 2025-03
Glaxosmithkline GBP 16.99B 927M 2024-12
Indivior 329M 4M 2025-03
J&J USD 52.25B 15.62B 2025-03
Medtronic USD 26.61B 1.72B 2025-01
Merck USD 37.11B 1.02B 2024-12
Neurocrine Biosciences USD 0 0 2024-12
Novartis USD 31.26B 828M 2024-12
Novartis USD 31.26B 828M 2024-12
Novo Nordisk 56.97B 88M 2024-09
Perrigo USD 3.62B 1.14B 2024-12
Pfizer USD 64.35B 3.35B 2024-12
Prestige Brands USD 996.95M 54.86M 2024-12
Regeneron Pharmaceuticals USD 2.7B 400K 2025-03
Roche Holding CHF 34.44B 5.23B 2024-06
Sanofi 21.05B 3.14B 2025-03
Sanofi 17.91B 5.85B 2024-12
United Therapeutics USD 200M 100M 2025-03
Zoetis USD 6.57B 4M 2024-12



Eli Lilly GJELD - Gjeldende verdier, historiske data, prognoser, statistikk, diagrammer og økonomiske kalender - May 2025.